Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …

A better understanding of transcriptional evolution of IDH-wild-type glioblastoma may be
crucial for treatment optimization. Here, we perform RNA sequencing (RNA-seq)(n= 322 test …

The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

Cancer immunoediting is a hallmark of cancer that predicts that lymphocytes kill more
immunogenic cancer cells to cause less immunogenic clones to dominate a population …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Oncogene amplification on extrachromosomal DNA (ecDNA) is a common event, driving
aggressive tumor growth, drug resistance and shorter survival. Currently, the impact of …

Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …